These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9316672)

  • 1. Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits.
    Garrido JM; Mena MA; Correa C; Herraras O; Jorge P; Leenders K; Antonini A; Günther I; Psylla M; de Yébenes JG
    Clin Neuropharmacol; 1994 Jun; 17(3):270-6. PubMed ID: 9316672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Garrido et al.: "Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits".
    Da Prada M; Jorga KM
    Clin Neuropharmacol; 1996 Feb; 19(1):98-9. PubMed ID: 8867524
    [No Abstract]   [Full Text] [Related]  

  • 3. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
    Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
    Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to the treatment of age-related brain disorders.
    Da Prada M
    Can J Neurol Sci; 1991 Aug; 18(3 Suppl):384-6. PubMed ID: 1933685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.
    Heizmann P; Schmitt M; Leube J; Martin H; Saner A
    J Chromatogr B Biomed Sci Appl; 1999 Jul; 730(2):153-60. PubMed ID: 10448949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The part played by catechol-O-methyltransferase in the plasma kinetics of 3,4-dihydroxyphenylglycol and 3,4-dihydroxyphenylalanine in the anaesthetized rabbit.
    Friedgen B; Halbrügge T; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):155-61. PubMed ID: 8474536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
    Korlipara LV; Cooper JM; Schapira AH
    Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues.
    Zürcher G; Colzi A; Da Prada M
    J Neural Transm Suppl; 1990; 32():375-80. PubMed ID: 2089102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of catechol-O-methyltransferase inhibition on the plasma clearance of noradrenaline and the formation of 3,4-dihydroxyphenylglycol in the rabbit.
    Halbrügge T; Friedgen B; Ludwig J; Graefe KH
    Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb; 347(2):162-70. PubMed ID: 8474537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
    Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE
    Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
    Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
    Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST; Ernst ME
    Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats.
    Napolitano A; Zürcher G; Da Prada M
    Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.
    Tunbridge EM; Bannerman DM; Sharp T; Harrison PJ
    J Neurosci; 2004 Jun; 24(23):5331-5. PubMed ID: 15190105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.